PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Institute of Medical Biochemistry, Center for Molecular Biology of Inflammation, and \'Cells in Motion\' Interfaculty Centre, University of Muenster, Muenster, Germany.\', \'Interdisciplinary Centre for Clinical Research, University of Muenster, Muenster, Germany.\', \'Institute of Virology, Center for Molecular Biology of Inflammation, and \'Cells in Motion\' Interfaculty Centre, University of Muenster, Muenster, Germany.\']
?:citedBy
  • -1
?:creator
?:doi
  • 10.1080/22221751.2020.1829082
?:doi
?:hasPublicationType
?:journal
  • Emerging microbes & infections
is ?:pmid of
?:pmid
?:pmid
  • 32975484
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • -1.0
?:rankingScore_hIndex
  • -1
is ?:relation_isRelatedTo_publication of
?:title
  • Targeting the endolysosomal host-SARS-CoV-2 interface by clinically licensed functional inhibitors of acid sphingomyelinase (FIASMA) including the antidepressant fluoxetine.
?:type
?:year
  • 2020

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/32975484>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/32975484>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all